Annexin Pharmaceuticals AB (publ) (STO:ANNX)
Sweden flag Sweden · Delayed Price · Currency is SEK
12.85
-0.10 (-0.77%)
Jun 11, 2026, 5:03 PM CET

STO:ANNX Balance Sheet

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
17.0727.416.3421.4231.1149.48
Cash & Short-Term Investments
17.0727.416.3421.4231.1149.48
Cash Growth
-62.26%67.69%-23.71%-31.17%-37.12%172.88%
Other Receivables
0.740.380.422.631.861.02
Receivables
0.740.380.422.631.861.02
Prepaid Expenses
0.630.790.630.870.670.22
Total Current Assets
18.4428.5717.3824.9233.6550.72
Property, Plant & Equipment
1.091.121.081.171.261.35
Long-Term Investments
0.310.310.310.310.410.15
Other Intangible Assets
0.140.160.270.370.470.58
Other Long-Term Assets
----0.89-
Total Assets
19.9830.1619.0426.7636.6852.79
Accounts Payable
2.952.972.964.333.333.51
Accrued Expenses
2.291.931.983.32.431.7
Other Current Liabilities
0.330.330.390.320.770.84
Total Current Liabilities
5.565.225.327.956.536.06
Other Long-Term Liabilities
-0-----
Total Liabilities
5.565.225.327.956.536.06
Common Stock
11.6811.688.825.742.5627.45
Additional Paid-In Capital
386.61386.61341.36299.29269.63220.91
Retained Earnings
-383.87-373.36-336.46-286.21-242.16-201.63
Comprehensive Income & Other
----0.12-
Shareholders' Equity
14.4224.9313.7118.8130.1546.73
Total Liabilities & Equity
19.9830.1619.0426.7636.6852.79
Net Cash (Debt)
17.0727.416.3421.4231.1149.48
Net Cash Growth
-62.26%67.69%-23.71%-31.17%-37.12%172.88%
Net Cash Per Share
2.424.143.6112.8221.2760.31
Filing Date Shares Outstanding
7.067.065.333.471.541.37
Total Common Shares Outstanding
7.067.065.333.471.541.37
Working Capital
12.8723.3412.0616.9727.1244.66
Book Value Per Share
2.043.532.575.4319.5234.05
Tangible Book Value
14.2824.7713.4518.4429.6846.15
Tangible Book Value Per Share
2.023.512.525.3219.2133.63